Treatment of complicated colorectal cancer. Evaluation of the outcome

被引:2
|
作者
Saliangas K. [1 ,2 ]
Economou A. [1 ]
Nikoloudis N. [1 ]
Andreadis E. [1 ]
Prodromou K. [1 ]
Chrissidou M. [1 ]
Topsis D. [1 ]
Chrissidis T. [1 ]
机构
[1] Department of Surgery, General Hospital of Edessa
[2] Veria 59100
关键词
Bleeding; Complicated colorectal cancer; Obstruction; Perforation;
D O I
10.1007/s10151-004-0156-3
中图分类号
学科分类号
摘要
A comparison of the outcome of 66 patients with complicated colorectal cancer (CRC) who underwent an emergency operation and 217 electively operated patients in an 11-year period was retrospectively determined. The complications presented on admission were obstruction (13.4%), perforation with peritonitis (6.36%), obstruction and perforation (1.4%) and massive bleeding (2.1%). The majority of the patients electively treated were of stages II and III (45.5% and 29%) and those urgently operated on were stages III and IV (67.7% and 14.1%) respectively. Radical resections were performed in 45 patients and palliative in 21. Only ten patients from the urgently treated are still alive and free of the disease. In conclusion, the treatment of complicated CRC carries a considerable incidence of complications, morbidity and mortality, and the overall 5-year survival rate is disappointing compared to electively treated patients.
引用
收藏
页码:S199 / S201
页数:2
相关论文
共 50 条
  • [21] Complicated colorectal cancer
    Kriwanek, S
    Armbruster, C
    Beckerhinn, P
    Lebisch, E
    Gschwantler, M
    CHIRURG, 1999, 70 (01): : 59 - 65
  • [22] Adjuvant treatment in extreme elderly patients with colorectal cancer.
    Cuquerella, Marta Llopis
    Castaño, Maria del Carmen Ors
    Espinosa, Maria Ballester
    Cremades, Alejandra Magdaleno
    Aracil, Vicente Boix
    Belloch, Maria del Rocio Ramirez
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [23] A study of the efficacy of gastrimmune in the adjuvant treatment of colorectal cancer.
    Henwood, M
    Smith, AM
    Watson, SA
    Justin, T
    Michaeli, D
    Grimes, S
    Bush, D
    Scholefield, JH
    Hardcastle, JD
    GASTROENTEROLOGY, 2000, 118 (04) : A518 - A519
  • [24] CEA: A therapeutic target for the treatment of advanced colorectal cancer.
    Majumdar, Avijit
    Li, Ying
    Lin, Sue-Hwa
    Mishra, Lope
    CANCER RESEARCH, 2013, 73 (08)
  • [25] Apatinib as a salvage treatment for refractory metastatic colorectal cancer.
    Chen, Xiaofeng
    Li, Ping
    Sun, Jing
    Wang, Biao
    Lin, Peinan
    Cai, Xiaomin
    Han, Xiao
    Gu, Yanhong
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] The effect of age on the treatment of stage III colorectal cancer.
    Lesko, S. M.
    Coleman, T.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2006, 163 (11) : S107 - S107
  • [27] Interstitial pneumonitis after oxaliplatin treatment in colorectal cancer.
    Yagüe X.H.
    Soy E.
    Merino B.Q.
    Puig J.
    Fabregat M.B.
    Colomer R.
    Clinical and Translational Oncology, 2005, 7 (11) : 515 - 517
  • [28] Metastasectomy and BRAF mutation: An analysis of survival outcome in metastatic colorectal cancer.
    Prasanna, Thiru
    Wong, Rachel
    Price, Timothy Jay
    Shapiro, Jeremy David
    Tie, Jeanne
    Wong, Hui-Li
    Nott, Louise M.
    Roder, David
    Lee, Margaret
    Kosmider, Suzanne
    Jalali, Azim
    Burge, Matthew E.
    Padbury, Robert
    Maddern, Guy
    Moore, James
    Carruthers, Scott
    Sorich, Michael
    Karapetis, Christos Stelios
    Gibbs, Peter
    Yip, Desmond
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [29] Application and evaluation of fecal SDC2 gene methylation in the diagnosis and treatment of colorectal cancer.
    Xie, Rongjia
    Liu, Zhuqing
    Xu, Qing
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] An international patient-centered outcome measurement set for colorectal cancer.
    Mamon, Harvey J.
    Zerillo, Jessica A.
    Schouwenburg, Maartie Gisele
    van Bommel, Annelotte
    Stowell, Caleb
    Van de Velde, Cornelis J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)